Form 4: ENDRA Life Sciences Director Receives RSU Grant

ENDRA Life Sciences Director Anthony DiGiandomenico was granted 60,324 restricted stock units, vesting in full by January 21, 2027.

Summary

• Anthony DiGiandomenico, a Director of ENDRA Life Sciences Inc. (NDRA), acquired 60,324 shares of common stock.
• The transaction occurred on January 21, 2026, and represents restricted stock units (RSUs) that convert to common stock on a one-for-one basis.
• The RSUs were acquired at a price of $0, indicating they are likely part of an equity compensation plan.
• These RSUs will vest in full on January 21, 2027.
• Following this transaction, DiGiandomenico beneficially owns 136,589 shares, which includes these newly acquired and other unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard practice of aligning director interests with shareholders through equity compensation. It's not highly impactful on its own but generally viewed favorably.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation at a $0 price indicates a grant rather than a purchase, a common practice for director remuneration.

Future Outlook

The restricted stock units granted to Director DiGiandomenico are scheduled to vest in full on January 21, 2027, indicating a future milestone for this equity compensation.

Industry Context

The grant of restricted stock units to a director is a standard practice in corporate governance and executive compensation across various industries, aiming to align the interests of leadership with long-term shareholder value.

Related Party Transactions

• The acquisition of restricted stock units by Anthony DiGiandomenico, a Director of ENDRA Life Sciences Inc., constitutes a related party transaction as it involves equity compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be seen as a positive for shareholders, as it ties a portion of the director's compensation directly to the company's future stock performance, fostering alignment of interests.

Next Steps

• The 60,324 restricted stock units will vest in full on January 21, 2027, at which point they will convert to common stock.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant